Literature DB >> 22202072

The contrasting oncogenic and tumor suppressor roles of FES.

Peter A Greer1, Shigeru Kanda, Thomas E Smithgall.   

Abstract

The FES gene was first discovered as a protein-tyrosine kinase-encoding retroviral oncogene. The ability of v-FES to transform cells in vitro and initiate cancer in vivo has been established by cell culture, engraftment and transgenic mouse studies. The corresponding cellular c-FES proto-oncogene encodes a cytoplasmic FES protein-tyrosine kinase with restrained catalytic activity relative to its retrovirally encoded homologs. These observations have stimulated a search for mutations or inappropriate expression of c-FES in human cancers and research aimed at understanding the functions of the FES kinase and its potential involvement in cancer and other diseases. Paradoxically, although first identified as an oncogene, genetic evidence has also implicated c-fes as a potential tumor suppressor. This review will describe observations from basic and translational research which shapes our current understanding of the physiological, cellular and molecular functions of the FES protein-tyrosine kinase and its potential roles in tumorigenesis. We also propose a model to reconcile the conflicting oncogenic and tumor suppressor roles of c-FES in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22202072     DOI: 10.2741/280

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  2 in total

1.  Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

Authors:  Sabine Hellwig; Chandra V Miduturu; Shigeru Kanda; Jianming Zhang; Panagis Filippakopoulos; Eidarus Salah; Xianming Deng; Hwan Geun Choi; Wenjun Zhou; Wooyoung Hur; Stefan Knapp; Nathanael S Gray; Thomas E Smithgall
Journal:  Chem Biol       Date:  2012-04-20

2.  Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.

Authors:  Mark C Weir; Sabine Hellwig; Li Tan; Yao Liu; Nathanael S Gray; Thomas E Smithgall
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.